Docoh
Loading...

MDNA Medicenna Therapeutics

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Friday
14 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Friday's session, 445 companies made new 52-week lows.
Medicenna Therapeutics Reports Regulatory Clearance To Expand Phase 1/2 ABILITY Study Of MDNA11 To Canada
17 Dec 21
Biotech, News, FDA, General
-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States -- Preliminary update on safety and PK/PD data expected by
Medicenna Therapeutics Shares Rise In Price On Low Volume; Traders Circulate Seeking Alpha Blog Post From Contributor BioSci Capital Partners's Blog Titled 'IBI Research On Medicenna: A Platform Technology Innovator To Decimate Cancers'
8 Dec 21
Movers, Trading Ideas
https://seekingalpha.com/instablog/17806842-biosci-capital-partners/5672758-ibi-research-on-medicenna-platform-technology-innovator-to-decimate-cancers
80 Biggest Movers From Yesterday
17 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.
53 Stocks Moving In Tuesday's Mid-Day Session
16 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss.
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
12 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Medicenna Therapeutics Q2 EPS $(0.12)
12 Nov 21
Earnings, News
Medicenna Therapeutics (NASDAQ:MDNA) reported quarterly losses of $(0.12) per share.
Earnings Scheduled For November 12, 2021
12 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million.
Medicenna Therapeutics Reports FDA Clearance Of Investigational New Drug Application To Expand Phase 1/2 ABILITY Study Of MDNA11 To US
27 Oct 21
Biotech, News, FDA, General
-- ABILITY Study is currently ongoing at clinical trial sites in Australia -- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 -- Initial efficacy data update expected in

Press releases

From Benzinga Pro
Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee
17 Jan 22
News, Health Care, Management, Press Releases
TORONTO and HOUSTON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that Mann Muhsin has
Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study
22 Dec 21
Health Care, Analyst Ratings, Press Releases, General
-- Peak CD8+ T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial's first two dose escalation cohorts -- MDNA11-induced increases in CD8+ T and NK cells
Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada
17 Dec 21
Health Care, Press Releases
-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States -- Preliminary update on safety and PK/PD data expected by
Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology
18 Nov 21
Health Care, Press Releases, General
TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that John H.
Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States
27 Oct 21
Health Care, Press Releases
-- ABILITY Study is currently ongoing at clinical trial sites in Australia -- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 -- Initial efficacy data update expected in mid-2022